-
新型冠状病毒肺炎(COVID-19),是一种由新型冠状病毒(SARS-CoV-2)感染而导致的急性呼吸系统传染病,以飞沫传播和接触传播为主要传播途径,患者多呈现出发热、乏力、干咳等症状,重症患者还表现出呼吸困难,呼吸系统衰竭等。自2019年12月疫情爆发以来,COVID-19以传染性强、潜伏期长、传播速度快等特点迅速引起国内外关注,并于2020年1月30日被世界卫生组织(WHO)列入“国际关注的突发卫生事件”[1]。基于SARS病毒与新冠肺炎病毒的高度同源性,连花清瘟即被应用于COVID-19的治疗中。截止目前,连花清瘟胶囊已被列入了很多国家和地区的COVID-19诊疗方案[2]。因此,根据已有的实验研究成果以及相关临床数据,结合连花清瘟胶囊化学性质与药物作用特点,对其成分与功效等研究进展进行归纳综述,以期为连花清瘟抗病毒机制研究和新冠肺炎临床治疗提供参考。
Research progress on chemical composition and clinical efficacy of Lianhua Qingwen (LHQW) capsule, a traditional Chinese medicine (TCM) used to treat COVID-19
-
摘要: 新型冠状病毒肺炎(COVID-19)疫情的爆发对人类健康与社会稳定造成了巨大威胁。随着病毒在全球迅速蔓延,针对新型冠状病毒(SARS-CoV-2)的药物开发及其相关研究成为医学领域的迫切问题。COVID-19归入中医学理论中的疫病范畴,连花清瘟胶囊(颗粒)屡次在重大疫情中发挥重要作用。既往研究表明,连花清瘟胶囊可能抑制MERS-CoV、SARS-CoV等多种病毒的生物活性。该文整理了历年国内外有关连花清瘟胶囊相关研究成果,从其化学成分、临床功效以及药理作用等方面进行综述分析,以期对连花清瘟胶囊抗病毒机制研究和新冠肺炎临床治疗提供科学依据。Abstract: The outbreak of COVID-19 posed a huge threat to human health and social stability. With the rapid spread of the virus around the world, the drug development and related research of novel coronavirus (SARS-CoV-2) have become an urgent issue in the medical field. COVID-19 fails into the category of epidemics in the theory of TCM. LHQW capsule has repeatedly played an important role in many major epidemics. Previous studies have shown that LHQW capsule can inhibit the biological activity of varied viruses including MERS-CoV and SARS-CoV. The paper summarizes the relevant research data and achievements of LHQW capsule in the past few years, reviews the chemical constituents, clinical efficacy and pharmacological effects of LHQW capsule, and provides scientific basis for the anti-virus mechanism of LHQW capsule and clinical treatment of COVID-19.
-
Key words:
- COVID-19 /
- Lianhua Qingwen capsule /
- pharmacological activity
-
[1] 世界卫生组织. 关于2019新型冠状病毒疫情的《国际卫生条例(2005) 》突发事件委员会第二次会议的声明[EB /OL]. (2020-01-30) [2020-02-10]. [2] 张伯礼. 中医药在新冠肺炎疫情防治中发挥了哪些作用[N]. 学习时报, 2020-03-18(6). [3] 刘金平, 贾伟娜, 李东, 等. 连花清瘟胶囊原料药的化学成分研究[J]. 天然产物研究与开发, 2015, 27(11):1887-1891. [4] 孙汉青, 李锦萍, 刘力宽, 等. 大黄化学成分与药理作用研究进展[J]. 青海草业, 2018, 27(01):47-51. doi: 10.3969/j.issn.1008-1445.2018.01.010 [5] 窦颖, 杨叁平. 连花清瘟胶囊: 天然抗生素, 广谱抗病毒[J]. 中国社区医师, 2012, 28(35):9. [6] 莫红缨. 连花清瘟胶囊防治流感病毒FM1感染小鼠的实验研究[C]//中医药优秀论文选(下). 北京: 中华中医药学会, 2009: 829-834. [7] 姚开涛, 刘明瑜, 李欣, 等. 中药连花清瘟治疗新型冠状病毒肺炎的回顾性临床分析[J]. 中国实验方剂学杂志, 2020, 26(11):8-12. [8] 程德忠, 王文菊, 李毅, 等. 51例新型冠状病毒肺炎患者应用中药连花清瘟疗效分析: 多中心回顾性研究[J/OL]. 天津中医药: 1-6[2020-05-09]. http://kns.cnki.net/kcms/detail/12.1349.R.20200310.1024.004.html. [9] 吕睿冰, 王文菊, 李欣. 连花清瘟颗粒联合西药常规疗法治疗新型冠状病毒肺炎疑似病例63例临床观察[J]. 中医杂志, 2020, 61(8):655-659. [10] 韩传映. 连花清瘟颗粒对小儿肺炎支原体肺炎细胞免疫功能影响研究[J]. 亚太传统医药, 2017, 13(5):137-139. doi: 10.11954/ytctyy.201705058 [11] FERRARA J L, ABHYANKAR S, GILLILAND D G. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1[J]. Transplant Proc,1993,25(1 Pt 2):1216-1217. [12] 李贝金, 李潇, 薛嘉睿, 等. 新冠肺炎炎症风暴的机制探讨及中医药的干预作用[J/OL]. 中国实验方剂学杂志: 1-8[2020-05-09]. https://doi.org/10.13422/j.cnki.syfjx.20201323. [13] CASADEVALL A, PIROFSKI L A. Microbiology: Ditch the term pathogen[J]. Nature,2014,516(7530):165-166. doi: 10.1038/516165a [14] LI C G, YANG P H, ZHANG Y L, et al. Corticosteroid treatment ameliorates acute lung injury induced by 2009 swine origin influenza a (H1N1) virus in mice[J]. PLoS One,2012,7(8):1-7. [15] IMAI Y, KUBA K, NEELY G G, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury[J]. Cell,2008,133(2):235-249. doi: 10.1016/j.cell.2008.02.043 [16] HUANG F M, GUO J, ZOU Z, et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients[J]. Nat Commun,2014,5(1):3595. doi: 10.1038/ncomms4595 [17] BETAKOVA T, KOSTRABOVA A, LACHOVA V, et al. Cytokines induced during influenza virus infection[J]. Curr Pharm Des,2017,23(18):2616-2622. [18] 何黎黎, 龚普阳, 封玥, 等. 中药在抗新型冠状病毒肺炎(COVID-19)引起的细胞因子风暴中的应用分析[J]. 中草药, 2020, 51(6):1375-1385. doi: 10.7501/j.issn.0253-2670.2020.06.002 [19] 张欣悦, 高永翔. 中药的免疫抑制作用研究进展[J]. 中药与临床, 2016, 7(1):59-61. [20] 国家卫生健康委办公厅、国家中医药管理局办公室. 新型冠状病毒感染的肺炎诊疗方案(试行第7版)[S]. 国卫办医函[2020]184号. (2020-03-10) [2020-03-03]. [21] DING Y W, ZENG L J, LI R F, et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function[J]. BMC Complementary Altern Med,2017,17(1):1-11. doi: 10.1186/s12906-016-1505-2 [22] 刘茜, 王荣帅, 屈国强, 等. 新型冠状病毒肺炎死亡尸体系统解剖大体观察报告[J]. 法医学杂志, 2020, 36(1):21-23. [23] 王林, 杨志华, 张浩然, 等. 连花清瘟治疗新型冠状病毒(2019-nCoV)肺炎网络药理学研究与初证[J]. 中药材, 2020, 43(3):772-778. [24] 马青龙, 张立婷, 杨文柯, 等. 新型冠状病毒细胞受体ACE2的研究进展[J]. 兰州大学学报(医学版), 2020, 46(2):70-75. [25] LI W H, MOORE M J, VASILIEVA N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus[J]. Nature,2003,426(6965):450-454. doi: 10.1038/nature02145 [26] LAN J, GE J W, YU J F, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor[J]. Nature,2020,581(7807):215-220. doi: 10.1038/s41586-020-2180-5 [27] YAN R H, ZHANG Y Y, LI Y N, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2[J]. Science,2020,367(6485):1444-1448. doi: 10.1126/science.abb2762 [28] CHEN X F, WU Y L, CHEN C, et al. Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening[J]. Acta Pharm Sin B,2021,11(1):222-236. doi: 10.1016/j.apsb.2020.10.002 [29] LI M H, LU Y, ZHANG L, et al. Association of cytokines with alanine aminotransferase, hepatitis B virus surface antigen and hepatitis B envelope antigen levels in chronic hepatitis B[J]. Chin Med J (Engl),2018,131(15):1813-1818. doi: 10.4103/0366-6999.237394 [30] HAAGMANS B L, KUIKEN T, MARTINA B E, et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques[J]. Nat Med,2004,10(3):290-293. doi: 10.1038/nm1001 [31] 马元元, 张中文, 李华伟, 等. 连翘酯苷对IFN-α和Mx1表达的影响[J]. 中国农业科学, 2010, 43(15):3237-3243. doi: 10.3864/j.issn.0578-1752.2010.15.023 [32] 范建新, 秦雪梅, 李震宇. 基于网络药理学和分子对接技术的款冬花在清肺排毒汤治疗新型冠状病毒肺炎(COVID-19)中的作用分析[J]. 中草药, 2020, 51(09):2317-2325. [33] 凌晓颖, 陶嘉磊, 孙逊, 等. 基于网络药理学的连花清瘟方抗冠状病毒的物质基础及机制探讨[J]. 中草药, 2020, 51(7):1723-1730. doi: 10.7501/j.issn.0253-2670.2020.07.006 [34] HOPKINS A L. Network pharmacology[J]. Nat Biotechnol,2007,25(10):1110-1111. doi: 10.1038/nbt1007-1110
计量
- 文章访问数: 7808
- HTML全文浏览量: 3624
- PDF下载量: 113
- 被引次数: 0